Skip to main content

Table 1 Patient characteristics of responders and non-responders

From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Variable Total n = 115 Responders n = 34 Non-responders n = 81 p-value
Sex
Female 15 (13.0%) 7 (20.6%) 8 (9.9%) 0.1196
Male 100 (87.0%) 27 (79.4%) 73 (90.1%)
Age, years
Mean (SD) 65.3 (8.7) 66.1 (7.8) 65.0 (9.1) 0.5156
Median (IQR) 65.0 (12.0) 67.0 (13.0) 65.0 (12.0)
Age category, years
  ≤ 65 55 (47.8%) 15 (44.1%) 40 (49.4%) 0.606
  > 65 60 (52.2%) 19 (55.9%) 41 (50.6%)
Ethnicity
Missing 10 (8.7%) 4 (11.8%) 6 (7.4%) 0.6638
Hispanic or Latin 5 (4.8%) 1 (3.3%) 4 (5.3%)
Other 100 (95.2%) 29 (96.7%) 71 (94.7%)
Race
Missing 11 (9.6%) 4 (11.8%) 7 (8.6%) 0.2326
Black 2 (1.9%) 0 2 (2.7%)
Other 3 (2.9%) 2 (6.7%) 1 (1.4%)
White 99 (95.2%) 28 (93.3%) 71 (95.9%)
ECOG status
0 90 (78.3%) 27 (79.4%) 63 (77.8%) 0.8463
1 25 (21.7%) 7 (20.6%) 18 (22.2%)
HCC diagnosis by:
Missing 2 (1.7%) 1 (2.9%) 1 (1.2%) 0.7518
EASL criteria 50 (43.5%) 13 (38.2%) 37 (45.7%)
Histology 50 (43.5%) 15 (44.1%) 35 (43.2%)
Other 13 (11.3%) 5 (14.7%) 8 (9.9%)
Hepatitis B
No 104 (90.4%) 31 (91.2%) 73 (90.1%) 0.8609
Yes 11 (9.6%) 3 (8.8%) 8 (9.9%)
Hepatitis C
No 81 (70.4%) 26 (76.5%) 55 (67.9%) 0.3581
Yes 34 (29.6%) 8 (23.5%) 26 (32.1%)
Alcohol etiology
No 63 (54.8%) 16 (47.1%) 47 (58.0%) 0.2809
Yes 52 (45.2%) 18 (52.9%) 34 (42.0%)
Previous therapies
TACE 28 (24.3%) 9 (26.5%) 19 (23.5%) 0.7311
TAE 2 (1.7%) 0 2 (2.5%) 0.3553
Resection 21 (18.3%) 9 (26.5%) 12 (14.8%) 0.1398
RFA 12 (10.4%) 6 (17.6%) 6 (7.4%) 0.1012
Brachytherapy 5 (4.3%) 1 (2.9%) 4 (4.9%) 0.6318
Max. diameter of largest lesion
Mean (SD) 68.0 (59.6) 69.8 (85.5) 67.3 (44.6) 0.2678
Median (IQR) 57.0 (45.0) 50.0 (40.0) 59.5 (52.0)
Portal vein infiltration
Yes 60 (52.2%) 21 (61.8%) 39 (48.1%) 0.1822
Baseline metastasis
Yes 6 (5.2%) 0 6 (7.4%) 0.1031
BCLC
B 34 (29.6%) 9 (26.5%) 25 (30.9%) 0.6375
C 81 (70.4%) 25 (73.5%) 56 (69.1%)  
Up-to-7 criterion
Inside 17 (14.8%) 7 (20.6%) 10 (12.3%) 0.2558
Outside 98 (85.2%) 27 (79.4%) 71 (87.7%)
Total bilirubin (μmol/L)
Mean (SD) 16.1 (7.1) 15.4 (7.3) 16.3 (7.1) 0.4752
Median (IQR) 14.9 (10.0) 14.4 (9) 15.0 (9.5)
Albumin g/L
Mean (SD) 37.8 (8.3) 38.9 (8.5) 37.4 (8.2) 0.3823
Median (IQR) 39.0 (7.7) 39.9 (6.5) 39.0 (8.0)
ALBI score
Mean (SD) −2.5 (0.7) −2.6 (0.8) −2.4 (0.7) 0.2331
Median (IQR) −2.5 (0.8) −2.7 (0.7) −2.5 (0.7)
Child-Pugh score
A 105 (91.3%) 33 (97.1%) 72 (88.9%) 0.1559
B 10 (8.7%) 1 (2.9%) 9 (11.1%
  1. ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, EASL European Association for the Study of the Liver, ECOG Eastern Cooperative Oncology Group, HCC hepatocellular carcinoma, IQR interquartile range, RFA radiofrequency ablation, SD standard deviation, TACE transarterial chemoembolization, TAE transarterial embolization